Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
about
Feline mammary adenocarcinoma: tumor size as a prognostic indicatorPlasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.Methodological challenges in the evaluation of prognostic factors in breast cancer.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus.Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.Protease nexin-1 expression is altered in human breast cancer.Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodiesPeroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator SystemuPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patientsTumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cellsEmerging biomarkers in breast cancer care.uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell lineEnhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells.A novel mode of intervention with serine protease activity: targeting zymogen activation.Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer.Rethink radiotherapy - BIGART 2017.Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer
P2860
Q24633496-72427190-743C-47FC-803D-722AE69AA131Q30307084-C8792BCC-B809-4503-AD35-2A46FF618883Q30311208-C80BC84E-95A5-4802-9979-E229568A1B2FQ33538459-8A39E9E1-5BDA-4AF5-B66E-C25DFD489D79Q33676610-DEB95639-6864-4089-BDDE-7F1AC1F67F8EQ33940503-B6723FB4-BE2E-4421-B1C3-C0D58D2AFDB0Q34370103-17C93A00-2732-4566-B84A-7F91615C8AA2Q34434875-FDE7F64E-F3CD-4E8E-A3A0-67EAE788BA28Q34768102-DD66F6A8-71AB-4125-9211-F18DA7DF3680Q34996841-CA348FC7-1FBA-48F2-9231-60EAE40AD3BDQ35431906-62D69C77-D2A1-496C-A17F-4D9719E3BF4CQ35495620-55B3F1B3-1773-495D-9F1F-74EA92B1A0D5Q35580701-0746A871-D840-469B-9B7F-6A02015E3DA5Q36615378-14B5816D-C2FE-463B-B213-8553A5A9D69CQ36617900-0666DA56-9B6C-4ABC-9F99-8A621A82AD8CQ36640228-0619073A-69BF-46CD-8BE9-7A216AC6025EQ36647843-AC6CDC49-4A38-437E-A019-1778DA8F5F95Q36761523-BDF1ADD1-1135-4B7C-9BEB-1168F5105987Q37137516-7E5A86FF-2E31-4114-9B63-4EFFE854AF26Q37779305-A092E9A8-53BC-4B00-88DD-CF5B39E820E8Q38817198-79181D46-9C2E-4B43-A511-85585A33A9A7Q39735763-4163FD27-ED8C-460F-90E8-CC7F6B4C669EQ39910451-1A83ED78-ECD8-4E07-98AB-5252284D14A5Q40288670-5E934846-6A1A-47A4-B706-F5AECAC3F293Q43705156-63CDFA5B-94AB-427C-9AF1-ECEB82ED4570Q43760328-AA176A85-00F6-49D0-A76C-00509AB5F1BCQ43770510-B8A80BBE-A85A-4811-89DA-F985DE9C4978Q43997799-4819B199-6047-4CF3-8549-9B191EF642D0Q44102084-8B01918B-8C39-44D3-B0FA-CC06E52D519EQ44439079-8D934E90-42F6-436C-9086-7F59D4834487Q48282380-95DD181A-217C-4EA0-98C2-B22C31D16300Q57581296-80753C28-B0B5-461C-A919-42393EBC90FE
P2860
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Prognostic significance of uro ...... or-1 in primary breast cancer.
@ast
Prognostic significance of uro ...... or-1 in primary breast cancer.
@en
type
label
Prognostic significance of uro ...... or-1 in primary breast cancer.
@ast
Prognostic significance of uro ...... or-1 in primary breast cancer.
@en
prefLabel
Prognostic significance of uro ...... or-1 in primary breast cancer.
@ast
Prognostic significance of uro ...... or-1 in primary breast cancer.
@en
P2093
P2860
P356
P1476
Prognostic significance of uro ...... tor-1 in primary breast cancer
@en
P2093
A C Simonsen
A V Laenkholm
J A Andersen
J Andersen
J Overgaard
P A Andreasen
P2860
P2888
P304
P356
10.1038/BJC.1998.154
P407
P577
1998-03-01T00:00:00Z